Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
Background. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. Objectives. Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum en...
Saved in:
Main Authors: | Hande Erman (Author), Engin Beydogan (Author), Seher Irem Cetin (Author), Banu Boyuk (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigation of comorbidities of COVID-19 patients with hepatosteatosis using latent class analysis
by: Ozge Pasin, et al.
Published: (2022) -
Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
by: Carmela Morace, et al.
Published: (2023) -
Cardiac biomarkers in coronary slow flow: Endocan and omentin-1
by: Kaan Okyay
Published: (2019) -
Ceramides: Nutrient Signals that Drive Hepatosteatosis
by: Scott A. Summers
Published: (2020) -
Immunohistochemical Expression of Endocan in Ameloblastoma
by: Salam N. Jawad, et al.
Published: (2016)